Clinical and Pathologic Studies in Neuroendocrine Tumors
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | April 9, 2008 | ||||
| Last Updated Date | February 26, 2010 | ||||
| Start Date ICMJE | July 2007 | ||||
| Estimated Primary Completion Date | June 2008 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE | Not Provided | ||||
| Original Primary Outcome Measures ICMJE | Not Provided | ||||
| Change History | Complete list of historical versions of study NCT00657332 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Clinical and Pathologic Studies in Neuroendocrine Tumors | ||||
| Official Title ICMJE | Clinical and Pathologic Studies in Neuroendocrine Tumors | ||||
| Brief Summary | This research involves the study of neuroendocrine tumors in order to better understand how the disease grows and spreads. This study requires will use tissue collected from from biopsies performed during your regular medical care (i.e. tissue leftover after your diagnosis has been made) and/or blood and urine samples. This study may lead to the development of special materials that could be used, in the future, to treat neuroendocrine tumors or to follow the response of neuroendocrine tumors to treatment |
||||
| Detailed Description | Not Provided | ||||
| Study Type ICMJE | Observational | ||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Retention: Samples Without DNA Description: biopsy of tumor, blood sample and/or urine samples. |
||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | neuroendocrine tumor patients |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE |
|
||||
| Study Group/Cohort (s) | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Terminated | ||||
| Estimated Enrollment ICMJE | 200 | ||||
| Estimated Completion Date | June 2008 | ||||
| Estimated Primary Completion Date | June 2008 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:- Patients are eligible if they have a histologically proven neuroendocrine tumor and are 18 years of age or older - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:None |
||||
| Gender | Both | ||||
| Ages | 18 Years and older | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | United States | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00657332 | ||||
| Other Study ID Numbers ICMJE | SU-12102007-931, 98132, END0005 | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| Responsible Party | George Albert Fisher M.D. Ph.D., Stanford University School of Medicine | ||||
| Study Sponsor ICMJE | Stanford University | ||||
| Collaborators ICMJE | Not Provided | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Stanford University | ||||
| Verification Date | February 2010 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||